Please login to the form below

Not currently logged in
Email:
Password:

Watson faces lawsuit over generic contraceptive

Warner Chilcott issues challenge over copycat version of Lo Loestrin Fe

Watson Pharmaceuticals

Warner Chilcott gone to court in the US to block Watson Pharmaceutical's attempt to market a generic version of its contraceptive Lo Loestrin Fe.

Ireland-based pharma firm Warner Chilcott filed a lawsuit in the New Jersey District Court following Waton's filing of an abbreviated new drug application with the US Food and Drug Administration (FDA) ahead of the drug's patent expiration.

Warner Chilcott told Bloomberg the Watson version would infringe two patents and it is seeking a court order to prevent sales until the separate patents expire in July 2014 and February 2029.

If the court does not rule in favour of Watson, the FDA would be prevented from granting a final approval for Waton's ANDA for 30 months.

Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol), a loss dose contraceptive, had US sales of $86m for the 12 months ending March 31, 2012.

Warner Chilcott has been involved in previous lawsuits regarding its franchise of Loestrin contraceptives.

In 2010, the company settled with Lupin Pharmaceuticals over its bid to launch generic versions of Loestrin 24 Fe and Femcon Fe, with Lupin agreeing to hold off on launching Loestrin 24 Fe and being granted a nono-exclusive licence to sell Femcom Fe.

Both Watson and Warner Chilcott are also look set to undergo several changes over the next few years, with the latter announcing that it was in talks with potential buyers in May 2012.

Meanwhile, Watson is in the middle of taking over Iceland-headquartered Actavis in a €4.3bn deal, which will "dramatically enhance our commercial position on a global basis, and brings complementary products and capabilities in the US”, according to its CEO Paul Bisaro.

21st May 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....